Pneumonia Testing Market Report

Market Overview:

The global pneumonia testing market size reached US$ 1.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.5 Billion by 2028, exhibiting a growth rate (CAGR) of 7.4% during 2023-2028.

Pneumonia is an infection in the lower respiratory tract caused by bacteria, viruses and fungi. It spreads via the inhalation of airborne droplets from the sneeze or cough of an infected person. It leads to inflammation in the air sacs of the lungs and shortness of breath. It also reduces appetite and causes mild fever, dry cough, headaches, fatigue, chills and chest pain. It is diagnosed through pneumonia testing, which includes a physical examination, medical history review, chest X-ray, blood culture, pulse oximetry, sputum culture, bronchoscopy, and fluid sample.

Pneumonia Testing Market Trends:

At present, there is a rise in the utilization of point of care (POC) testing to detect pneumonia on account of its higher efficiency and rapid and accurate test results. This, along with the burgeoning healthcare industry, represents one of the key factors driving the market. Moreover, the introduction of immunochromatographic, pneumococcal urinary antigen (UAT) and advanced nucleic acid detection tests is propelling the growth of the market. In addition, the growing awareness among individuals about the benefits of early diagnosis is augmenting the number of pneumonia testing across the globe. This, coupled with the rising healthcare expenditure by governments of several countries, is contributing to the growth of the market. Besides this, there is an increase in the adoption of enzyme-linked immunosorbent assay (ELISA) to detect pneumonia as it is highly sensitive and easier to carry out. Other growth-inducing factors are the growing geriatric population and rising prevalence of pneumonia among children around the world. Furthermore, key market players are focusing on new product launches and approvals which is projected to bolster the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global pneumonia testing market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, method, technology and end user.

Breakup by Type:

• Analyzers
• Consumables
   

Breakup by Method:

• Immunodiagnostics
• Molecular Diagnostics
• Point of Care Testing
   

Breakup by Technology:

• Enzyme-linked Immunosorbent Assay
• Immunofluorescence
• Western Blot
• Polymerase Chain Reaction
• Immunohistochemistry
• Others
   

Breakup by End User:

• Hospitals
• Diagnostic Laboratories
• Homecare
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories Inc, Curetis GmbH (OpGen), DiaSorin S.p.A., Hologic Inc, Meridian Bioscience Inc, Quest Diagnostics Incorporated, Quidel Corporation, Roche Holding AG, and Thermo Fisher Scientific Inc.

Report Coverage: